The rising number of cell and gene therapies advancing toward clinical trials and eventual commercialization hold the potential to treat a number of diseases with previously unmet needs. With six new therapies approved in 2022, including the first allogeneic T-cell therapy, and at least as many slated for approval this year, the sector is poised for rapid growth.
However, many challenges remain in this nascent industry. Developers must provide innovative solutions to navigate the shifting regulatory landscape and employ efficient, reliable manufacturing processes to reduce costs and ensure product efficacy. Review the white paper to learn more about the challenges – such as gene insertion and immunogenicity – that hinder advancement as well as exciting possibilities for expanded applications in the future.